US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
NASDAQ
Jasper Therapeutics Inc (JSPR)
Jasper Therapeutics Inc (JSPR) ニュース

Jasper Therapeutics Inc (JSPR)

0.466

0.0377

(8.80%)

終了 7月7日 5:00AM

0.4628

-0.0032

( -0.69% )

プレマーケット: 5:00PM

個人投資家向けのプロ仕様のツール。

プレミアム

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a...

Jasper Therapeutics shares rise 5% on clinical updates despite Q4 loss

Jasper Therapeutics Inc. (NASDAQ:JSPR) reported a fourth-quarter loss of $0.32 per share for the period ending December 31, 2025. The company...

Jasper Shares Surge Following Encouraging Early Asthma Trial Data

Jasper Therapeutics Inc. (NASDAQ:JSPR) jumped 17.4% in premarket trading Tuesday after the company released promising initial findings from its...

Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR

Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR PR Newswire LOS...

Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR

Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR PR Newswire LOS...

Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR

Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR PR Newswire LOS...

Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR

Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR PR Newswire LOS...

Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR

Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR PR Newswire LOS...

JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit

Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR

JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit

Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR

81vette

81vette 2月前

Bought 20k so far ave .90,bids in for more if it dips

81vette

81vette 2月前

https://investorshub.advfn.com/stock-market/NASDAQ/jasper-therapeutics-JSPR/trades

iHub News

iHub News 3月前

Jasper Therapeutics shares rise 5% on clinical updates despite Q4 lossMarch 31, 2026 10:32 AM
IH Market News
Jasper Therapeutics Inc. (NASDAQ:JSPR) reported a fourth-quarter loss of $0.32 per share for the period ending December 31, 2025. The company currently generates no revenue, as it remains focused on clinical development of its lead drug candidate, briquilimab.Despite the loss, the biotechnology company’s shares climbed 5.44% in pre-market trading following the announcement, as investors reacted positively to recent clinical progress rather than the quarterly financial results.In January, Jasper said that 67% of additional patients enrolled in Cohort 9.1 of the BEACON study achieved a complete response at 12 weeks, with a mean UAS7 score reduction of 31 points.The company also reported that 75% of chronic spontaneous urticaria patients participating in the open-label extension study achieved either a complete response or well-controlled disease at 12 weeks.“Briquilimab has demonstrated the potential for a compelling and differentiated profile in both CSU and CIndU, along with proof of concept in asthma,” said Jeet Mahal, President and Chief Executive Officer of Jasper.“We are very pleased with the chronic urticaria data we reported in January from the BEACON study as well the open-label extension study, which reaffirmed the potential of briquilimab to drive rapid and durable disease control in patients,” he added.The company plans to begin enrolling patients in the Phase 2b portion of its Phase 2b/3 clinical study in chronic spontaneous urticaria during the second half of 2026, subject to available funding.Research and development expenses totaled $11.4 million in the fourth quarter, while general and administrative costs reached $4.5 million.For the full year 2025, Jasper reported a net loss of $75.8 million, or $3.95 per share. The company ended the year with $28.7 million in cash and cash equivalents, down from $71.6 million a year earlier.Jasper Therapeutics stock price

Original: Jasper Therapeutics shares rise 5% on clinical updates despite Q4 loss

81vette

81vette 6月前

Macd Crossed to bullish on 5 day chart,watching closely as death hr is ending at 11:30

glenn1919

glenn1919 7月前

JSPR..........................................................https://stockcharts.com/sc3/ui/?s=JAPR&p=W&b=5&g=0&id=p86431144783

INV4

Institutional Ownership 72.51%

Total Shares Outstanding (millions) 28
Total Value of Holdings (millions) $35

Active Positions | Holders | Shares
Increased Positions | 31 | 9,960,459
Decreased Positions | 39 | 2,336,667
Held Positions | 12 | 7,994,814
Total Institutional Shares | 82 | 20,291,940

https://www.nasdaq.com/market-activity/stocks/jspr/institutional-holdings

================

Jasper Therapeutics Analyst Ratings and Price Targets | NASDAQ:JSPR | Benzinga
Jasper Therapeutics Inc has a consensus price target of $25.7 based on the ratings of 18 analysts. The high is $86 issued by Stifel on June 27, 2024. The low is $4 issued by RBC Capital on November 11, 2025. The 3 most-recent analyst ratings were released by RBC Capital, Evercore ISI Group, and JMP Securities on November 11, 2025, September 22, 2025, and September 22, 2025, respectively. With an average price target of $8 between RBC Capital, Evercore ISI Group, and JMP Securities, there's an implied 296.04% upside for Jasper Therapeutics Inc from these most-recent analyst ratings.

https://www.benzinga.com/quote/JSPR/analyst-ratings

(Price targets are not always met)

$JSPR

tw0122

1.93 Casper and Jasper

tw0122

$2.10 Jasper the friendly ghost has risen

jgrabar

jgrabar 9月前

GRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF SHAREHOLDERS OF JASPER THERAPEUTICS, INC. (NASDAQ: JSPR)
Grabar Law Office is investigating claims on behalf of shareholders of Jasper Therapeutics, Inc. (NASDAQ: JSPR). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased Jasper Therapeutics, Inc. (NASDAQ: JSPR), shares prior to November 30, 2023, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, Jasper shares between November 30, 2023 and July 3, 2025, you can participate in the class action Please visit https://grabarlaw.com/the-latest/jasper-shareholder-investigation/, contact Joshua Grabar at jgrabar @FH-6085.
JSPR

ErnieBilco

ErnieBilco 12月前

JSPR getting murderized this morning. $2.30 on bad drug lot news, results were positive but the drug lot problem killed it.

Monksdream

Monksdream 1年前

JSPR reports 5/19 according to Seeking Alpha

Yo-Yo

Looks like things may be perking up around here!!! Let's get dem super 7's tomorrow and then some!!!

Golden Cross

Golden Cross 1年前

Are we expecting another rebound boom this time around?

Golden Cross

Golden Cross 1年前

tw0122

In some $5.60s what's the story here on beat down from $20

Sly1969

Sly1969 1年前

Entered today. 6.95 average. Bids sitting 6.90

Sly1969

Sly1969 1年前

Entered today. 6.95 average. Bids sitting 6.90

Monksdream

Monksdream 2年前

tw0122

Rinse repeat back to $19 get out and play to $17

tw0122

$15.87 + 5% low floater 10m .Most missed the early run to $19 rinse repeat

08:22 AM EDT, 10/14/2024 (MT Newswires) -- Jasper Therapeutics (JSPR) said Monday that preliminary data from its phase 1b/2a study of briquilimab showed that 93% of the adult participants with cold urticaria or symptomatic dermographism in both dose groups showed a clinical response to the treatment within six weeks.

In the 120mg dose cohort, 83% of participants experienced a complete response, the company said, adding briquilimab was well tolerated with no serious adverse events.

Jasper said that it secured regulatory clearance to enroll a 180mg dose cohort for the study and expects to report full trial data in the first half of 2025.

Shares of Jasper were up more than 15% in recent Monday premarket activity.

Monksdream

Monksdream 2年前

JSPR in an uptrend

ipo_dude

ipo_dude 2年前

Lets go. On out way to 30

Monksdream

Monksdream 2年前

JSPR 10Q due March 7

FROZENFLAME

FROZENFLAME 3年前

Nice thanks moving to $SUNW 52WL !

FROZENFLAME

FROZENFLAME 3年前

Looking good 90s is next thin !

FROZENFLAME

FROZENFLAME 3年前

90s very soon !

FROZENFLAME

FROZENFLAME 3年前

Nice squeeze at this level will be nice !
Waiting

FROZENFLAME

FROZENFLAME 3年前

https://ir.jaspertherapeutics.com/news-releases/news-release-details/jasper-therapeutics-announces-ind-clearance-phase-1b2a-study

FROZENFLAME

FROZENFLAME 3年前

https://x.com/wkrbnews/status/1709554398584578412?s=46&t=SOfgYFcNY1OxgkraPxHd4g

FROZENFLAME

FROZENFLAME 3年前

Pressure building up, let’s POP !

FROZENFLAME

FROZENFLAME 3年前

Let’s see some 90s and close the week strong !

FROZENFLAME

FROZENFLAME 3年前

FROZENFLAME

FROZENFLAME 3年前

FROZENFLAME

FROZENFLAME 3年前

80s close will be great !

FROZENFLAME

FROZENFLAME 3年前

Bid and volume creeping up, we need to hit 80s and I think the rest will be history, sure we will find out .

FROZENFLAME

FROZENFLAME 3年前

Nice healthy trading, next leg up should be coming soon, IMO .

FROZENFLAME

FROZENFLAME 3年前

Should see some 80s tomorrow, IMO .

FROZENFLAME

FROZENFLAME 3年前

Waiting !
$JSPR

FROZENFLAME

FROZENFLAME 3年前

Very thin all the way to 80s !

FROZENFLAME

FROZENFLAME 3年前

FROZENFLAME

FROZENFLAME 3年前

Interesting PPS !

Jayzp

jspr vs ther

Strong buy ther
Reddit stock news

https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html

INFINITI

INFINITI 3年前

Yes it can today is day one hold tight $$$$&

dennisv

dennisv 3年前

This Can Fly High!

dennisv

dennisv 3年前

55 Minutes To Go!

INFINITI

INFINITI 3年前

SQUEEZE EM to $3 let’s gooooo$$$

Invest-in-America

Invest-in-America 3年前

JSPR: Kick-ASS!!!!

Triple nickle

Triple nickle 3年前

INFINITI

INFINITI 3年前

Looking good I’m in $$$$ let’s goooo

makinezmoney

makinezmoney 3年前

$JSPR: Just spiked there to $2.10

Boooooooommmmmmmmmmmmmmmmmm

GO $JSPR

Jasper Therapeutics

Gen Dynamics DRN

Intercontinental Interna...

1.5% Nts 19oct2029

ETFS Long JPY Short EUR

Anglogold Ashanti

Canadian Fixed Income Co...

Xtrackers Developed Gree...

Compass Venture

Croghan Bancshares (QB)

RSE Archive (GM)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。